Cargando…
An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real‐world practice setting: A report from the Fenfluramine European Early Access Program
OBJECTIVE: To examine the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) in three age groups: <6, 6‐17, and ≥18 years old, treated in a real‐world setting. METHODS: Patients with DS were treated with fenfluramine in the European Union Early Access Program (EAP). Followi...
Autores principales: | Guerrini, Renzo, Specchio, Nicola, Aledo‐Serrano, Ángel, Pringsheim, Milka, Darra, Francesca, Mayer, Thomas, Gil‐Nagel, Antonio, Polster, Tilman, Zuberi, Sameer M., Lothe, Amélie, Gammaitoni, Arnold, Strzelczyk, Adam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712464/ https://www.ncbi.nlm.nih.gov/pubmed/35801621 http://dx.doi.org/10.1002/epi4.12624 |
Ejemplares similares
-
Fenfluramine: New Treatment for Seizures in Dravet Syndrome
por: Pierce, Joanna Garcia, et al.
Publicado: (2020) -
Fenfluramine significantly reduces day‐to‐day seizure burden by increasing number of seizure‐free days and time between seizures in patients with Dravet syndrome: A time‐to‐event analysis
por: Sullivan, Joseph, et al.
Publicado: (2021) -
A review of fenfluramine for the treatment of Dravet syndrome patients
por: Simon, Kayla, et al.
Publicado: (2021) -
Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes
por: Frampton, James E.
Publicado: (2023) -
Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study
por: Lai, Wyman W., et al.
Publicado: (2020)